How to prepare
Preparation is based on the ESGO Curriculum (European Training Requirements).
We recommend:
- ESGO Textbook (available via eAcademy)
- ESGO Guidelines
- Recommended reading list (updated annually)
Topics covered
Questions include organ specific questions, including:
- Ovarian and tubal cancer
- Uterine cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer
- Gestational trophoblastic disease
- Miscellaneous
As well as generic modules, including:
- GMP
- Clinical cancer genetics
- Systemic therapy
- Radiotherapy
- Pathology
- Psycho-oncology
- Sexual health
- Palliative and supportive care
- Peri-operative care
- Urological surgery
- Plastic surgery, wound care
- Radiology
- Research, methodology
Example questions
Palliative and supportive care
-
- Depression
- Nausea
- Pain
- Spiritual or existential crisis
Ovarian and tubal cancer
-
- PARP inhibitors are most effective only in patients with a known germline BRCA.
- PARP inhibitors are well-tolerated, with gastrointestinal symptoms being the most common side effect.
- Maintenance therapy with PARP inhibitors is typically reserved for patients who achieve a complete response after chemotherapy.
- The risk of secondary haematological malignancies exists but is relatively rare.
Pathology
-
- Extensive stromal invasion
- Pseudostratified columnar epithelium
- Psammoma bodies
- Signet ring cells
Radiology
-
- To measure the thickness of the myometrium
- To act as a negative contrast agent by instilling fluid or gel into the uterine cavity
- To avoid the use of ultrasound in endometrial assessment
- To enhance the echogenicity of the ovaries
Systemic Therapy
-
- The recommended second-line systemic treatment is combined therapy of pembrolizumb and lenvatinib.
- The recommended second-line systemic treatment is non-platinum chemotherapy such as doxorubicin or paclitaxel.
- The recommended second-line systemic treatment is endocrine therapy based on progestins.
- Rechallenge with platinum-based chemotherapy is not an option for second-line treatment as it was already administrated as first-line treatment.
Vulvar cancer
-
- Infiltration of the upper third of the urethra is classified as prognostically equivalent to regional lymph node metastasis with extracapsular spread.
- Infiltration of the upper third of the vagina is classified as prognostically equivalent to fixed or ulcerated inguinal lymph node metastasis.
- Pelvic lymph node metastases are classified as prognostically equivalent to metastases in distant organs.
- Ulcerated inguinal lymph node metastases are classified as prognostically equivalent to metastases in distant organs.
Urological surgery
-
- …the bladder and ureters are removed.
- …the bladder is removed.
- …the urethra and bladder are removed.
- …the urethra, bladder, and ureters are removed.
Research and methodology
-
- Odds ratio
- Hazard ratio
- Risk ratio (relative risk)
- Attributable risk
Sexual health
-
- Histological tumour type, tumour dimension, nodal status, and tumour location
- Histological tumour type, nodal status, clear resection margins, and lymphovascular space invasion (LVSI)
- Tumour dimension, nodal status, LVSI, age, and comorbidities
- Tumour location, nodal status, LVSI, age, and comorbidities
GTD
-
- Liver
- Bone
- Lymph nodes
- Lungs